Abstract
Modulating brain oscillations has strong therapeutic potential. However, commonly used non-invasive interventions such as transcranial magnetic or direct current stimulation have limited effects on deeper cortical structures like the medial temporal lobe. Repetitive audio- visual stimulation, or sensory flicker, modulates such structures in mice but little is known about its effects in humans. Using high spatiotemporal resolution, we mapped and quantified the neurophysiological effects of sensory flicker in human subjects undergoing presurgical intracranial seizure monitoring. We found that flicker modulates both local field potential and single neurons in higher cognitive regions, including the medial temporal lobe and prefrontal cortex, and that local field potential modulation is likely mediated via resonance of involved circuits. We then assessed how flicker affects pathological neural activity, specifically interictal epileptiform discharges, a biomarker of epilepsy also implicated in Alzheimer’s and other diseases. In our patient population with focal seizure onsets, sensory flicker decreased the rate interictal epileptiform discharges. Our findings support the use of sensory flicker to modulate deeper cortical structures and mitigate pathological activity in humans.
Competing Interest Statement
ACS owns shares of Cognito Therapeutics. Her conflicts are managed by Georgia Tech.
Clinical Trial
NCT04188834
Funding Statement
A.C.S. acknowledges the Packard Foundation and NIH NINDS R01 NS109226; J.T.W. acknowledges NIH NIMH R01 MH120194-01A1. LTB was in part supported by DARPA-BAA-14-08, U01NS113198, NIMH R01 MH120194-01A1 and the Georgia Tech/Emory NIH/NIBIB Training Program in Computational Neural-engineering (T32EB025816).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study-related procedures were approved by the Emory Institutional Review Board. The study was registered at clinicaltrials.gov under NCT04188834.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interests statement: ACS owns shares of Cognito Therapeutics. Her conflicts are managed by Georgia Tech.
Data Availability
De-identified, minimally processed data and processed data, will be made available upon request.
